Alliance Global Partners Initiates Coverage On INmune Bio with Buy Rating, Announces Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
Alliance Global Partners has initiated coverage on INmune Bio with a Buy rating and set a price target of $20.
October 21, 2024 | 11:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alliance Global Partners has initiated coverage on INmune Bio with a Buy rating and a price target of $20, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $20 by Alliance Global Partners suggests a positive sentiment towards INmune Bio. This is likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100